Geode Capital Management LLC Trims Stock Holdings in IDEAYA Biosciences, Inc. $IDYA

Posted by Stanley Muller on Jun 9th, 2026

Geode Capital Management LLC reduced its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 3.6% during the 4th quarter, Holdings Channel reports. The fund owned 2,073,583 shares of the company’s stock after selling 76,450 shares during the period. Geode Capital Management LLC’s holdings in IDEAYA Biosciences were worth $71,695,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in IDYA. Farther Finance Advisors LLC lifted its position in shares of IDEAYA Biosciences by 171.1% in the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in IDEAYA Biosciences in the third quarter valued at $38,000. ANTIPODES PARTNERS Ltd increased its stake in IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new position in IDEAYA Biosciences in the third quarter valued at $58,000. Finally, Global Retirement Partners LLC acquired a new position in IDEAYA Biosciences in the fourth quarter valued at $61,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wells Fargo & Company upped their target price on IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Friday, May 22nd. Royal Bank Of Canada upped their target price on IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $58.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, June 2nd. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.69.

View Our Latest Analysis on IDYA

IDEAYA Biosciences Stock Performance

IDYA stock opened at $31.48 on Tuesday. IDEAYA Biosciences, Inc. has a 1 year low of $20.50 and a 1 year high of $39.28. The firm has a market cap of $2.77 billion, a P/E ratio of -19.68 and a beta of -0.04. The stock has a 50-day simple moving average of $30.18 and a 200-day simple moving average of $32.62.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The firm had revenue of $6.56 million during the quarter, compared to analyst estimates of $5.04 million. During the same period in the prior year, the business posted ($0.82) EPS. The business’s quarterly revenue was down 39.4% on a year-over-year basis. On average, equities research analysts predict that IDEAYA Biosciences, Inc. will post -4.27 EPS for the current year.

IDEAYA Biosciences Company Profile

(Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.